Endocrine, Metabolic & Immune Disorders-Drug Targets

(Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)

Emilio Jirillo  
Universitá degli Studi di Bari
Dipartimento di Clinica Medica
Immunologia e Malattie Infettive
Sezione di Microbiologia e Immunologia
Piazza Giulio Cesare-Policlinico


A Novel Approach to Anticancer Therapies: Peroxisome Proliferator Activator-Receptor-γ as a New Target Therapy in the Treatment of Human Urological Cancer

Author(s): M. Matsuyama and R. Yoshimura

Affiliation: Department of Urology, Osaka City University Hospital, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545- 8585, Japan.


Peroxisome proliferator activator-receptor (PPAR)-γ is a ligand-activated transcriptional factor belonging to a steroid receptor superfamily. PPAR-γ plays a role in both adipocyte differentiation and carcinogenesis. Up-date, PPAR-γ is expressed in various cancer tissues, and PPAR-γ ligand induces growth arrest of these cancer cells. In this study, we examined the expression of PPAR-γ in human urological cancer (including renal cell carcinoma, bladder tumor, prostate cancer and testicular cancer) by RT-PCR and immunohistochemistry, and we also examined the effect of PPAR-γ ligand in these cells by MTT assay, flow cytometry and hoechest staining. PPAR-γ expression was significantly more extensive and intense in malignant tissues than in normal tissues. PPAR-γ ligand induced the reduction of malignant cell viability through early apoptosis. These results demonstrated that generated PPAR-γ in urological cancer cells may play an important role in carcinogensis and become a new target therapy in the treatment of urological cancer.

Keywords: Peroxisome proliferator activator-receptor-γ, apoptosis, renal cell carcinoma, bladder tumor, prostate cancer, testicular cancer

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [76 - 83]
Pages: 8
DOI: 10.2174/187153009787582432